GeneNews (TSX:GEN) has signed an agreement with a large, multi-specialty physician group in the American Midwest for use of its cancer diagnostic tests.
The contract represents GeneNews’ second partnership agreement with a U.S. healthcare services group and will mark the introduction of the company’s BreastSentry diagnostic test to the U.S. market.
The BreastSentry diagnostic has the potential to predict a patient's risk of developing breast cancer in the ensuing five years, as well as estimating lifetime risk.
Patients of the new medical group, which prefers not to have its name published, will now have access to GeneNews' innovative screening tests, including ColonSentry, earlyCDT-Lung, Prostate Health Index, and the new BreastSentry diagnostic test, which provide early risk stratification of colorectal, lung, prostate and breast cancers, respectively.
All four screenings utilize a quick and convenient blood test that can be completed through designated medical clinics.
GeneNews will process the samples through its CAP and CLIA-certified Innovative Diagnostic Laboratory clinical reference laboratory in Richmond, VA, and provide individualized risk stratification reports for each patient, the supply of testing kits and ongoing consultation.
Atlanta-based JTS Health Partners will work with both GeneNews and the medical group within the planning and implementation phase.
"As with most cancers, the early identification of high risk patients is critical to improved decision making and treatment,” GeneNews chairman and CEO, James Howard-Tripp, said in a statement.
“We are confident that [the BreastSentry] test will be well received by patients and look forward to making it more widely available throughout the U.S. in the coming months,” he added.